International news in seven languages
Topic
Popular diabetes and weight loss drugs such as Ozempic and Wegovy have been linked to a slightly increased risk of a rare condition that can cause sudden, potentially permanent vision loss. Although the risk remains very low, Rutgers researchers say the findings warrant attention as millions of people turn to GLP-1 medications.
Walmart will offer Novo's Ozempic and Lilly's Mounjaro without charge for people with Type 2 diabetes after a new prior authorization.
Scientists have developed an experimental injection that destroys fat cells and significantly reduces dangerous belly fat, potentially opening a new path to treating obesity. Early research also suggests it could help prevent the weight regain that often follows stopping popular weight loss drugs like Ozempic and Wegovy.
Popular GLP-1 weight loss drugs, such as Ozempic and Wegovy, have been linked to unexpectedly high rates of nail detachment, hair loss, and scalp inflammation, with some problems occurring several times more frequently among users. Researchers found that weight loss alone could not fully explain the differences, suggesting there may be more to these overlooked symptoms.
The criminal indictment in Florida comes as the use of GLP-1 drugs such as Novo's Ozempic for weight loss has hit new highs among U.S. adults.
Children taking GLP-1 medications (such as Victoza, Saxenda, Trulicity, and Ozempic) for weight loss, prediabetes, or type 2 diabetes may face an overlooked risk: nutritional deficiencies. A new study found that nearly 1 in 6 young patients developed a diagnosed deficiency within a year of starting treatment, with vitamin D deficiency affecting about 12%.
A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compared with those who stayed on them.
AI analysis of 400,000 Reddit posts found that users of drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound reported unexpected symptoms including menstrual changes, chills, hot flashes, and fatigue. Researchers cannot say the medications caused these problems, but the patterns may reveal overlooked signals worth studying.
Ozempic and other GLP-1 medications can improve blood sugar, weight, and cardiovascular health, but researchers found little evidence that they also improve mental health, employment, marriage, or overall well-being. The findings suggest the drugs’ broader life effects may be subtler than their dramatic physical health benefits.
